Background: The current anemia burden among US preschool children and women of childbearing age has not been documented.
Objective: We used data from National Health and Nutrition Examination Surveys 1988-1994 and 1999-2002 to examine recent anemia changes.
Design: We calculated the prevalence of anemia (hemoglobin < 11.0 g/dL at <24 mo, <11.1 g/dL at 24-59 mo, and <12.0 g/dL for women), iron deficiency anemia (anemia plus abnormal value >or=2: serum ferritin, transferrin saturation, and erythrocyte protoporphyrin), and high blood lead (>or=10 microg/dL) with anemia among children 12-59 mo and women 20-49 y in both surveys. Among women, we also calculated the prevalence of folate deficiency (erythrocyte folate < 317.2 nmol/L) with anemia and high C-reactive protein (>10 mg/L) with anemia. Multiple logistic regression was used to compare anemia prevalence between surveys, with control for race and age.
Results: Anemia declined significantly in children (from 8.0% to 3.6%; OR: 0.4; 95% CI: 0.3, 0.7) and women (10.8% to 6.9%; OR: 0.6; CI: 0.4, 0.7), but the prevalence of iron deficiency anemia did not change significantly in children (1.5% compared with 1.2%; OR: 0.7; 95% CI: 0.4, 1.5) or women (4.9% compared with 4.1%; OR: 0.8; 95% CI: 0.6, 1.1). Folate deficiency with anemia declined significantly in women (from 4.1% to 0.5%; OR: 0.1; 95% CI: 0.1, 0.2), but logistic regression models and standardization indicated that none of the known possible anemia causes could account for the decline in total anemia in children or women.
Conclusions: The prevalence of anemia declined significantly among US women and children between 1988-1994 and 1999-2002, but this decline was not associated with changes in iron or folate deficiency, inflammation, or high blood lead.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3945/ajcn.2008.25926 | DOI Listing |
Transpl Infect Dis
December 2024
Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
This case involves a 52-year-old male, who underwent a deceased donor orthotopic liver transplant 7 months prior, presented with a 2-week history of persistent fever, anemia, thrombocytopenia, and mild elevation of liver enzymes. Upon hospital admission, the patient was febbrile, alert and oriented, hemodynamically stable. Laboratory exams revealed worsening leukopenia, anemia, thrombocytopenia, hyponatremia, and elevated ferritin.
View Article and Find Full Text PDFAnn Hematol
December 2024
Department of Medical Oncology, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, 212 Yuhua East Road, Baoding, 071000, Hebei, China.
The first-line treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has recently undergone major changes, and targeted therapies have ushered in a new era of CLL/SLL treatment. Scientists in different countries have successively analyzed the efficacy of various drugs, but safety studies are relatively insufficient. Therefore, this systematic evaluation and retrospective meta-analysis was conducted to compare the differences in adverse effects and their incidence among first-line treatment regimens for CLL/SLL.
View Article and Find Full Text PDFAm J Case Rep
December 2024
I Department of Radiology and Diagnostic Imaging, Norbert Barlicki Memorial Teaching Hospital No. 1, Medical University of Łódź, Łódź, Poland.
BACKGROUND Arterioportal fistulas (APFs) are abnormal connections between the arterial and portal venous systems, leading to portal hypertension (PH) and symptoms such as gastrointestinal bleeding, splenomegaly, and hepatic pain. Symptoms typically appear by the age of 2 years in about 75% of cases. CASE REPORT A 7-year-old boy with an asymptomatic APF developed life-threatening complications following a Clostridium difficile infection.
View Article and Find Full Text PDFArthritis Res Ther
December 2024
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
Background: Thrombocytopenia (TP) is a hematological manifestation of systemic lupus erythematosus (SLE) and is associated with unfavorable prognostic outcomes. This study aimed to develop a risk prediction model for new-onset TP in SLE patients.
Methods: Based on the multicenter prospective Chinese SLE Treatment and Research Group (CSTAR) registry, newly diagnosed SLE patients without TP at registration were enrolled.
Int J Hematol
December 2024
Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Eltrombopag is used with first-line immunosuppressive therapy for adult aplastic anemia, although its practical utility in childhood remains unclear. We retrospectively analyzed the outcomes of pediatric patients who received eltrombopag in Japan. Of the 27 eligible patients, 23 (85%) were previously treated, and 15 (56%) had severe or very-severe disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!